These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37544876)

  • 21. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
    Licinio R; Losurdo G; Ierardi E; Di Leo A; Principi M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302. PubMed ID: 25968153
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.
    Braun J; Xiang J; Brandt J; Maetzel H; Haibel H; Wu P; Kohler S; Rudwaleit M; Siegert S; Radbruch A; Thiel A; Sieper J
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i85-9. PubMed ID: 11053096
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumour necrosis factor and septic shock.
    Waage A
    Lancet; 1998 Feb; 351(9102):603. PubMed ID: 9492815
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
    BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor.
    Singh P; Taylor SF; Murali R; Gomes LJ; Kanthan GL; Maloof AJ
    Clin Exp Ophthalmol; 2007 Apr; 35(3):275-80. PubMed ID: 17430516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.
    Kempeni J
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i44-5. PubMed ID: 11053087
    [No Abstract]   [Full Text] [Related]  

  • 27. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Eberhardson M; Söderling JK; Olén O
    Aliment Pharmacol Ther; 2018 Jan; 47(1):147-148. PubMed ID: 29226402
    [No Abstract]   [Full Text] [Related]  

  • 28. Comment on Williams NH, et al.: a systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica (Eur Spine J, 2013;22(9):1921-35).
    Wang J; Li GT; Sun HT
    Eur Spine J; 2014 Apr; 23(4):938. PubMed ID: 24435983
    [No Abstract]   [Full Text] [Related]  

  • 29. Commercially available antibodies to human tumour necrosis factor-alpha tested for cross-reactivity with ovine and bovine tumour necrosis factor-alpha using flow cytometric assays.
    Dernfalk J; Waller KP; Johannisson A
    Acta Vet Scand; 2004; 45(1-2):99-107. PubMed ID: 15535090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigenic structure of human tumour necrosis factor: recognition of distinct regions of TNF alpha by different tumour cell receptors.
    Rathjen DA; Cowan K; Furphy LJ; Aston R
    Mol Immunol; 1991; 28(1-2):79-86. PubMed ID: 1707138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.
    Paul S; Keat A
    Rheumatology (Oxford); 2005 Jan; 44(1):17-23. PubMed ID: 15328421
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 33. In situ detection of tumour necrosis factor in human ovarian cancer specimens.
    Naylor MS; Malik ST; Stamp GW; Jobling T; Balkwill FR
    Eur J Cancer; 1990; 26(10):1027-30. PubMed ID: 2148874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour necrosis factor inhibitors: maximizing patient safety.
    Cairns AP; Taggart AJ
    Rheumatology (Oxford); 2003 Jan; 42(1):188-9. PubMed ID: 12509638
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of tumor necrosis factor receptors in tumor necrosis factor-alpha-mediated cytolysis of ovarian cancer cell lines.
    Kost ER; Herzog TJ; Adler LM; Williams S; Mutch DG
    Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):145-53. PubMed ID: 8571998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of tumour necrosis factor-α antagonists in maintenance therapy for ulcerative colitis.
    Ng A
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1088. PubMed ID: 35048671
    [No Abstract]   [Full Text] [Related]  

  • 37. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.
    Bell S; Kamm MA
    Lancet; 2000 Mar; 355(9207):858-60. PubMed ID: 10752696
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-tumour necrosis factor alpha therapy: can we afford it?
    Symmons DP
    Ann Rheum Dis; 2005 Jul; 64(7):969-70. PubMed ID: 15958756
    [No Abstract]   [Full Text] [Related]  

  • 39. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade.
    Grunke M; Schulze-Koops H
    Ann Rheum Dis; 2006 Apr; 65(4):555-6. PubMed ID: 16531556
    [No Abstract]   [Full Text] [Related]  

  • 40. Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin.
    Liang CM; Liang SM; Jost T; Sand A; Dougas I; Allet B
    Biochem Biophys Res Commun; 1986 Jun; 137(2):847-54. PubMed ID: 3729942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.